Partner Spotlight: Coolfinity
Coolfinity is a Dutch healthcare infrastructure company specializing in resilient medical and vaccine refrigeration for settings with unreliable power. We design and manufacture WHO-listed cold-chain systems using patented ice-bank thermal batteries to safeguard vaccines and other temperature-sensitive medicines. Our refrigerators are deployed across more than 30 countries, primarily supporting healthcare delivery in the Global South, where power outages are frequent and severe.
Our Story
One project we are particularly proud of is our UPF-2 initiative in Ukraine, supported by the Netherlands Enterprise Agency (RVO). The project emerged from an urgent need to safeguard vaccines and essential medicines during the ongoing conflict, where damaged infrastructure and repeated power interruptions made conventional refrigeration unreliable. With immunisation programs and access to medicine at risk, a different approach was required to match the realities healthcare providers were facing.
Working alongside local and international partners, we are deploying Coolfinityโs thermal-battery-based refrigerators to public healthcare facilities across the country. Designed to maintain safe temperatures for extended periods without electricity, the units address core operational challenges on the ground. Close coordination between donors, partners, and healthcare providers enables fast deployment, making the project effective even under highly unstable conditions.
Role of TFHC
TFHC played a pivotal role by alerting us to the UPF-2 subsidy program, which made the project possible. They also strengthened our work by increasing our visibility within the Dutch and global health ecosystem and by facilitating connections with public-sector stakeholders and innovation partners. This support helped accelerate our international engagement and expand the reach of our work in public health settings.
Results & Next Steps
The UPF-2 project has measurably strengthened cold-chain resilience in Ukrainian healthcare facilities, reducing the risk of vaccine spoilage and medicine losses during repeated power disruptions. A key lesson was the value of designing refrigeration around real operating conditions, not ideal power scenarios, combined with early alignment with local implementation partners to support fast, effective deployment.
Building on these results, we are preparing follow-up deployments and expanding the use of our thermal-battery-based refrigeration in other fragile and low-resource health systems. Our next focus areas include Eastern Europe and the Global South, where reliable cold-chain infrastructure remains critical to safeguarding immunisation programs and essential medicines.
